Table 1
Component: DLin-MC3-DMA | Molecular weight: 642.11 | Reported molar entry: 40 | Calculated mass: Not calculated
sales@dcchemicals.com
DLin-MC3-DMA
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 1
Component: DSPC | Molecular weight: 790.15 | Reported molar entry: 10 | Calculated mass: Not calculated
Table 1
Component: Cholesterol | Molecular weight: 386.65 | Reported molar entry: 40 | Calculated mass: Not calculated
Table 1
Component: C18 dialkyl-ether PEG2000 carbamate | Molecular weight: Not confirmed | Reported molar entry: 10 | Calculated mass: Not calculated
Table 2
Component: DLin-MC3-DMA | Molecular weight: 642.11 | Reported molar entry: 50 | Calculated mass: Not calculated
Table 2
Component: DSPC | Molecular weight: 790.15 | Reported molar entry: 10 | Calculated mass: Not calculated
Table 2
Component: Cholesterol | Molecular weight: 386.65 | Reported molar entry: 38.5 | Calculated mass: Not calculated
Table 2
Component: PEG-lipid (optimized identity not independently resolved) | Molecular weight: Not confirmed | Reported molar entry: 1.5 | Calculated mass: Not calculated
Table 3
Parameter: Screening lipid phase | Reported procedure / limitation: MC3/DSPC/cholesterol/PEG-lipid 40:10:40:10 in ethanol; introduce into 50 mM citrate, pH 4, to final ethanol 30% v/v and lipid 6.1 mg/mL. | Source: SI PDF pp. 39–40
Table 3
Parameter: Preformed vesicles | Reported procedure / limitation: Equilibrate 2 min at room temperature; extrude through two stacked 80 nm filters at 22 °C, generally 1–3 passes, to the stated 70–90 nm screening size range. | Source: SI PDF p. 40
Table 3
Parameter: siRNA loading | Reported procedure / limitation: siRNA in 50 mM citrate pH 4 with 30% ethanol; add at approximately 5 mL/min to vesicles pre-equilibrated at 35 °C; incubate a further 30 min at 35 °C. | Source: SI PDF p. 40
Table 3
Parameter: Screening loading-ratio discrepancy | Reported procedure / limitation: Main article: siRNA:total lipid approximately 0.05 w/w; SI preparation target: 0.06 w/w. Their reciprocals are approximately 20:1 and 16.7:1 total lipid:siRNA. These are source-specific mass statements, not N/P. | Source: Main formulation paragraph; SI PDF p. 40
Table 3
Parameter: Buffer exchange | Reported procedure / limitation: Dialysis into PBS containing 155 mM NaCl, 3 mM Na2HPO4 and 1 mM KH2PO4, pH 7.5. Dialysis duration is not stated in the recovered method. | Source: SI PDF p. 40
Table 3
Parameter: Optimized monkey preparation | Reported procedure / limitation: Spontaneous-formation procedure cross-referenced to earlier papers; 50:10:38.5:1.5 composition. SI prints siRNA-to-lipid 0.9 w/w; this unresolved value is not silently changed to 0.09 or converted into a recommended preparation ratio. | Source: SI PDF p. 42, visually checked
Table 3
Parameter: Mouse assay | Reported procedure / limitation: Female C57BL/6 mice, 8–10 weeks; lateral-tail-vein injection in 10 mL/kg; serum collected at 24 h. FVII activity measured colorimetrically at 405 nm relative to saline control. | Source: SI PDF p. 40
Table 3
Parameter: Monkey assay | Reported procedure / limitation: Cynomolgus monkeys, n=3 per dose; siTTR 0.03, 0.1 or 0.3 mg/kg; 15-min cephalic-vein infusion, 5 mL/kg; liver sampled at 48 h. TTR mRNA normalized to GAPDH using branched-DNA assay. | Source: SI PDF pp. 42–43
Table 4
Measurement / batch: Apparent LNP pKa | Reported result: 6.44; duplicate titrations | Evidence context: SI Fig. S1, PDF p. 41. This is an in situ particle titration, not a universal neat-molecule constant.
Table 4
Measurement / batch: TNS method | Reported result: 100 µM lipid and 1 µM TNS; excitation 321 nm, emission 445 nm; half-maximal fitted fluorescence | Evidence context: SI PDF p. 41: HEPES/MES/ammonium acetate 10 mM each, NaCl 130 mM, pH 2.5–11. Main text describes pH 3–10; method versions remain distinguished.
Table 4
Measurement / batch: Size and dispersity boundary | Reported result: 70–90 nm and PDI 0.11 ± 0.04 summarize the 56-lipid screening library | Evidence context: Main text, n=56. Not an individually tabulated MC3 size/PDI or a specification for the optimized formulation.
Table 4
Measurement / batch: Product-specific EE / zeta potential | Reported result: No separately quantified MC3 value recovered for these formulations | Evidence context: Not filled from library averages or other papers.
Table 4
Measurement / batch: Product identity | Reported result: Lipid 16; C43H79NO2; molecular weight 642.11 | Evidence context: Main Fig. 4; supporting information
Table 5
Experiment and dose: Initial mouse FVII potency MC3 lipid 16 in the 40:10:40:10 composition; FVII siRNA IV; female C57BL/6 mice; four-dose screen, n=4 per dose | Readout and comparator: Readout: 24 h; serum FVII activity Comparator: Saline and other screened lipids | Result and source: Reported ED50 0.03 mg siRNA/kg. Do not attach the later 0.005 mg/kg value to this screening recipe. Main Table 1 and Figs. 3–5; SI PDF p. 40
Table 5
Experiment and dose: Optimized mouse FVII potency 50:10:38.5:1.5 composition; FVII siRNA IV; n=5 per dose | Readout and comparator: Readout: 24 h according to the FVII assay method Comparator: Saline; earlier screening composition | Result and source: Reported ED50 approximately 0.005 mg/kg, a sixfold lower dose than the 0.03 mg/kg screening value. Mean ± SD plotted; full optimized PEG / loading inputs remain unresolved. Main Fig. 7 inset; SI PDF p. 40
Table 5
Experiment and dose: Cynomolgus-monkey TTR silencing Optimized MC3-LNP; siTTR 0.03, 0.1 or 0.3 mg/kg; 15-min IV infusion; n=3/group | Readout and comparator: Readout: 48 h; liver TTR mRNA relative to GAPDH Comparator: Control-normalized hepatic TTR expression | Result and source: Reported ED50 <0.03 mg/kg. This is hepatic mRNA reduction, not serum TTR protein reduction or a clinical endpoint. Main Fig. 7; SI PDF pp. 42–43
Table 5
Experiment and dose: Mixed-lipid pKa / potency comparison FVII siRNA 0.1 mg/kg IV; mixed lipids 15/16/17 occupy the 40 mol% ionizable fraction; n=4 | Readout and comparator: Readout: 24 h; serum FVII activity Comparator: Pure lipid 16 (MC3) and pure lipids 15 or 17 | Result and source: An equimolar mixture of lipids 15 and 17 achieved pKa and activity similar to MC3; no tested mixture exceeded MC3 alone. These mixtures are separate materials, not a new pure-MC3 recipe. Main Fig. 6; SI Fig. S2
Table 5
Experiment and dose: In situ pKa determination 40:10:40:10 MC3 preformed vesicles; fluorescence titration in duplicate | Readout and comparator: Readout: Room-temperature TNS fluorescence Comparator: pH titration baseline and fitted maximum | Result and source: Mean apparent pKa 6.44. The library activity optimum near pKa 6.2–6.5 is specific to the studied hepatic siRNA system. SI Fig. S1; main Figs. 3–5